Evidence map›Paper›PMID 39735621›Full record

ArticleHeliyon2024

Biomarker potential of plasma cell-free DNA for cholangiocarcinoma.

Sattrachai Prasopdee, Sissades Tongsima, Montinee Pholhelm, Siraphatsorn Yusuk, Sithichoke Tangphatsornruang, Kritiya Butthongkomvong, Teva Phanaksri, Anthicha Kunjantarachot, Jutharat Kulsantiwong, Smarn Tesana and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Sattrachai PrasopdeeResearch Group in Multidimensional Health and Disease (MHD), Chulabhorn International College of Medicine, Thammasat University, Pathum Thani, 12120, Thailand.
Sissades TongsimaNational Biobank of Thailand (NBT), National Science and Technology Development Agency, Pathum Thani, 12120, Thailand.
Montinee PholhelmResearch Group in Multidimensional Health and Disease (MHD), Chulabhorn International College of Medicine, Thammasat University, Pathum Thani, 12120, Thailand.
Siraphatsorn YusukResearch Group in Multidimensional Health and Disease (MHD), Chulabhorn International College of Medicine, Thammasat University, Pathum Thani, 12120, Thailand.
Sithichoke TangphatsornruangNational Center for Genetic Engineering and Biotechnology, National Science and Technology Development Agency, Pathum Thani, 12120, Thailand.
Kritiya ButthongkomvongMedical Oncology Unit, Udonthani Cancer Hospital, Udon Thani, 41330, Thailand.
Teva PhanaksriChulabhorn International College of Medicine, Thammasat University, Pathum Thani, 12120, Thailand.
Anthicha KunjantarachotChulabhorn International College of Medicine, Thammasat University, Pathum Thani, 12120, Thailand.
Jutharat KulsantiwongFaculty of Science, Udon Thani Rajabhat University, Udon Thani, 41000, Thailand.
Smarn TesanaResearch Group in Multidimensional Health and Disease (MHD), Chulabhorn International College of Medicine, Thammasat University, Pathum Thani, 12120, Thailand.
Thanakrit SathavornmaneeChonburi Hospital, Ministry of Public Health, Chonburi, 20000, Thailand.
Veerachai ThitapakornResearch Group in Multidimensional Health and Disease (MHD), Chulabhorn International College of Medicine, Thammasat University, Pathum Thani, 12120, Thailand.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: To prevent the development of cholangiocarcinoma, an effective screening opisthorchiasis viverrini and/or differential diagnosis of and the cholangiocarcinoma is crucial needed. The level and quality of cfDNA in plasma are being investigated for their potential role as biomarkers in cholangiocarcinoma. Methods: The study enrolled 43 healthy controls (N), 36 Results: The results showed that cfDNA could effectively differentiate between N and OV from CCA statistically both by DNA amount and quality. Using a cut-off of >20.94 ng/ml, the sensitivity and specificity of the cfDNA concentration were determined to be 86.11% and 98.73% for the differential diagnosis of cholangiocarcinoma, respectively. The ULP-WGS with iChorCNA indicated the % tumor fraction of cfDNA ( Conclusion: The use of cfDNA concentration and ULP-WGS for analyzing DNA quality including % tumor fraction, ctDNA concentration, tumor ploidy, and SCNA are useful for the differential diagnosis of cholangiocarcinoma from opisthorchiasis viverrini and healthy individuals.

Indexed as

Cell-free DNACholangiocarcinomaCirculating tumor DNADiagnosisiChorCNAOpisthorchis viverriniUltra-low-pass whole-genome sequencing (ULP-WGS)

Identifiers

PMID39735621
PMCPMC11681853

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.